---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-021133"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T12:04:12.613595+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Alector reports Q4 net loss $41.4M; cash runway extended to 2026 after $75M equity offering

## Summary
- Q4 net loss $41.4M ($0.49/sh) vs $52.4M ($0.63) YoY; FY net loss $130.4M ($1.56) vs $133.3M ($1.62).
- Cash $548.9M at Dec 31; pro forma $620M after Jan 2024 equity offering, providing runway through 2026.
- INVOKE-2 Phase 2 enrollment completed (381 pts); data due Q4 2024. Latozinemab granted FDA Breakthrough Therapy for FTD-GRN.
- First patient dosed in PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early AD in Feb 2024.
- 2024 guidance: collaboration revenue $60-70M, R&D $210-230M, G&A $60-70M.

## SEC filing metadata
- accession: 0000950170-24-021133
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000095017024021133/0000950170-24-021133-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000095017024021133/alec-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-021133
- JSON: https://secwatch.observer/filing/0000950170-24-021133.json
- Plain text: https://secwatch.observer/filing/0000950170-24-021133.txt

## Key facts
- Earnings Releases
  Alector, Inc. reported financial results for the quarter ended December 31, 2023.
  - Period: the quarter ended December 31, 2023
  - Result: reported results
  source text: On February 27, 2024, Alector, Inc. (the “Company”) announced its financial results for the quarter ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1653087/000095017024021133/0000950170-24-021133-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.